Merck puts HQ on the auction block; Curemark raises $18.5M for autism; FDA accepts NDA from Keryx;

@FierceBiotech: Special Report: 10 top drugs in biopharma's late-stage pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: Want to buy a million-square-foot monument to Merck's past glory? More | Follow @JohnCFierce

@DamianFierce: The FDA outlines its shutdown activities--nothing that hasn't been reported, but a handy document no less. More | Follow @DamianFierce

> Merck ($MRK) has posted a "For Sale" sign on its 1-million-square-foot headquarters building in Whitehouse Station, NJ, as it prepares to downsize in the state. Story

> Rye, NY-based Curemark has raised $18.5 million as it seeks approval for a new drug to treat autism. Release

> The FDA has accepted Keryx's ($KERX) NDA for the chronic kidney disease drug Zerenex. Release

> Cell Therapeutics ($CTIC), which has struggled in the past on some significant performance metrics, has set up an SPA with the FDA on its Phase III study of pacritinib in myelofibrosis. Release

Medical Device News

@FierceMedDev: New special report: Med tech's hottest takeover targets for the rest of 2013. Feature | Follow @FierceMedDev

@MarkHFierce: Quest Diagnostics is expanding through a Peabody, MA acquisition (My old professional stomping grounds.) News | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Alnylam posts positive PhI for RNAi cholesterol drug. Story from FierceDrugDelivery | Follow @MichaelGFierce

> ProTip's artificial larynx successfully implanted in male patient. More

> Tandem seeks $100M IPO amid burgeoning market. Story

> Biomet buying Lanx with eye on spinal implants. News

Pharma News

@FiercePharma: Trending this a.m. online: Forget drug-sales forecasts, study finds. They're usually wrong. Who does it best? Article | Follow @FiercePharma

@CarlyHFierce: From FierceVaccines: GlaxoSmithKline targeting a 2015 launch for its malaria vaccine. Report | Follow @CarlyHFierce

> Supreme Court asks DoJ for input on whistleblower evidence standards. Story

> Forget a Roche merger; Novartis sell-offs could be imminent, analyst says. Article

> WSJ: Doc clears Biogen Idec's Tecfidera in patient's death. News

Pharma Manufacturing News

@EricPFierce: Projecting $140M annual operating losses, Boehringer says Ben Venue plant not worth keeping open. Story | Follow @EricPFierce

> Aesica fined $161,000 for worker injury. Report

> Sartorius picking up TAP Biosystems in $45M deal. Story

> Recipharm, Fujifilm expand their biologics capabilities. Article

> Ranbaxy may look to buy FDA-approved plant in India. Item

Biotech Research News

@EmilyMFierce: There's a Major Foodborne Illness Outbreak and the Government's Shut Down. More from Wired | Follow @EmilyMFierce

> Three U.S.-based scientists jointly win Nobel Prize for cell transport discoveries. Article

> $6.25M grant establishes leukemia research initiative. Item

> Yale team investigates promising new class of antidepressants. Story

> Chemical in red wine kills cancer cells even after it's metabolized. More

And Finally… Investigators say that PET imaging can highlight a key biomarker for aggressive lung tumors, helping physicians craft the right therapeutic plan for each patient. Release

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.